Aligos Therapeutics (ALGS) Assets Average (2021 - 2025)
Aligos Therapeutics (ALGS) has disclosed Assets Average for 5 consecutive years, with $99.1 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Assets Average rose 25.09% year-over-year to $99.1 million, compared with a TTM value of $99.1 million through Dec 2025, up 25.09%, and an annual FY2025 reading of $79.3 million, down 28.42% over the prior year.
- Assets Average was $99.1 million for Q4 2025 at Aligos Therapeutics, down from $122.2 million in the prior quarter.
- Across five years, Assets Average topped out at $249.2 million in Q4 2021 and bottomed at $79.3 million in Q4 2024.
- Average Assets Average over 5 years is $149.0 million, with a median of $134.2 million recorded in 2023.
- The sharpest move saw Assets Average plummeted 44.61% in 2023, then grew 25.09% in 2025.
- Year by year, Assets Average stood at $249.2 million in 2021, then crashed by 37.65% to $155.4 million in 2022, then dropped by 23.61% to $118.7 million in 2023, then tumbled by 33.22% to $79.3 million in 2024, then rose by 25.09% to $99.1 million in 2025.
- Business Quant data shows Assets Average for ALGS at $99.1 million in Q4 2025, $122.2 million in Q3 2025, and $142.7 million in Q2 2025.